Acclarent

ENT Surgical Devicesacclarent.com

Acclarent Inc. develops and commercializes minimally invasive ENT surgical devices, including the pioneering Balloon Sinuplasty system and the AI-enhanced TruDi Navigation System, sold to hospitals and surgical centers. Founded in 2004 and currently a subsidiary of Integra LifeSciences (acquired April 2024).

Company typePrivate
Founded2004
HeadquartersMenlo Park, United States
Headcount251–500
GTM typeB2B
OfferingHardware or Manufacturing

What Acclarent does

Acclarent Inc. is a medical device company that develops and commercializes minimally invasive technologies for the treatment of ear, nose, and throat (ENT) disorders, primarily chronic sinusitis. Founded in 2004 and headquartered in Menlo Park, California, the company pioneered Balloon Sinuplasty, a balloon sinus dilation technique that opened an alternative to traditional invasive sinus surgery, and later developed the TruDi Navigation System, an AI-enhanced surgical navigation platform that provides real-time instrument tracking during sinus procedures. The company holds FDA 510(k) clearances for its devices and serves hospitals and surgical centers performing ENT surgery through a direct enterprise field sales model.

Acclarent was originally venture-backed by Versant Ventures, New Enterprise Associates, Meritech Capital Partners, Delphi Ventures, and Johnson & Johnson Development Corporation, raising approximately $86 million across funding rounds from 2004 to 2009 before being acquired by Johnson & Johnson (via Ethicon) in 2010. Under J&J ownership, Acclarent operated as a division for over a decade, contributing to the J&J/Acclarent 14% share of the global ENT Surgical Devices market (valued at USD 3.487 billion in 2026), trailing Medtronic at 18%. In April 2024, Integra LifeSciences Holdings Corporation completed the acquisition of Acclarent from Ethicon, integrating it into Integra's surgical device portfolio.

The TruDi Navigation System was enhanced with AI algorithms in late 2021, after which FDA adverse event reports increased sharply — from roughly 8 malfunctions over three years to more than 100 — including strokes, cerebrospinal fluid leaks, and skull punctures. Two patients have filed lawsuits in Texas alleging the AI component caused surgical errors and injuries, representing a material regulatory and litigation exposure that affects the company's AI product trajectory and overall risk profile.

Acclarent firmographics

Firmographics

Name: Acclarent
Legal name: Acclarent Inc.
Website: https://acclarent.com
Company type: Private
Founded year: 2004
Operating status: Operating
Headcount range: 251–500 employees
Short description: Acclarent Inc. develops and commercializes minimally invasive ENT surgical devices, including the pioneering Balloon Sinuplasty system and the AI-enhanced TruDi Navigation System, sold to hospitals and surgical centers. Founded in 2004 and currently a subsidiary of Integra LifeSciences (acquired April 2024).
Ownership category
akta.pro rank

Acclarent industry classification

Industry

Product category: ENT Surgical Devices
NAICS: Surgical and Medical Instrument Manufacturing (339112), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)
SIC: Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro primary industry: Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG)
akta.pro secondary industries: General Otolaryngology (ENT) (HLAKAMAA), ENT / Otolaryngology Surgery Centers (HLAFAIAJ), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

ENT surgical devices
Balloon sinuplasty
Sinus surgery navigation
Minimally invasive ENT
Ear nose throat devices

Where Acclarent is headquartered

Location

Headquarters

HQ city: Menlo Park
HQ country: United States
HQ region: North America

Markets served

Acclarent business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

Medical Device Hardware Sales: Sale of ENT surgical devices including the TruDi Navigation System and Balloon Sinuplasty products to hospitals and surgical centers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Acclarent product offering

Product offering

Core offering

Acclarent develops and sells minimally invasive medical devices for ear, nose, and throat (ENT) surgical procedures, with a primary focus on chronic sinusitis treatment. Its flagship offerings are the Balloon Sinuplasty system, a pioneering balloon sinus dilation technology, and the TruDi Navigation System, an AI-enhanced image-guided surgical navigation platform. These devices are sold to hospitals, surgical centers, and ENT surgeons for use in sinus and related ENT procedures.

Product overview

Acclarent, now a division of Integra LifeSciences, offers a portfolio of minimally invasive ENT treatments centered around two key products: Balloon Sinuplasty (their pioneering balloon sinus dilation technology) and the TruDi Navigation System (an AI-enhanced surgical navigation system for sinus surgery). The company was originally founded in 2004 and acquired by Johnson & Johnson in 2010, then acquired by Integra LifeSciences in April 2024.

Differentiator

Problem solved

Functional benefit

Brands

Balloon Sinuplasty: Minimally invasive ENT treatment technology pioneered by Acclarent.
TruDi Navigation System

Products and services

Balloon Sinuplasty A pioneering minimally invasive balloon sinus dilation system used by ENT surgeons to open blocked sinus passages in patients with chronic sinusitis, offering an alternative to traditional invasive sinus surgery with reduced patient recovery time.
TruDi Navigation System An AI-enhanced image-guided surgical navigation system used by ENT surgeons during sinus surgery procedures to track surgical instrument locations in real time. The system received AI algorithm enhancements in late 2021.

Companies that use Acclarent

Customer profile

Segments1 record

Ideal customer profiles1 record

Acclarent technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Acclarent partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered major.

Integra LifeSciencesmajorStrategic or Co-development Partner · 1 April 2024In April 2024, Integra LifeSciences Holdings Corporation completed the acquisition of Acclarent Inc. from Ethicon (Johnson & Johnson), expanding its surgical device offerings through Acclarent's ENT technologies including the TruDi Navigation System.
Johnson & JohnsonmajorStrategic or Co-development Partner · 1 January 2010Acclarent was acquired by Johnson & Johnson in 2010, becoming a division of J&J. The company was originally founded with Fund II in 2004 and pioneered Balloon Sinuplasty technology. J&J held approximately 14% global market share in ENT surgical devices.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Acclarent competitors and assessment

Company assessment

Direct peers

Medtronic: Medtronic is the global leader in ENT surgical devices with ~18% share vs. Acclarent's ~14%, directly competing in sinus surgery navigation, powered instruments, and balloon dilation.
Intersect ENT: Intersect ENT (now part of Medtronic) developed sinus drug-eluting implants and propels steroid implants, directly adjacent to Acclarent's minimally invasive sinus treatment franchise.
Spirox / Entellus Medical (Stryker): Entellus (acquired by Stryker) and Spirox focused on in-office balloon sinus dilation systems, directly competing with Acclarent's Balloon Sinuplasty platform.
Karl Storz SE & Co. KG: Karl Storz is a leading ENT endoscopy and instrument specialist directly comparable to Acclarent's surgical device portfolio for sinus and otolaryngology procedures.

Broad incumbents

Smith+Nephew: Smith+Nephew is a diversified surgical device incumbent with ENT-adjacent offerings and shared hospital sales channels overlapping Acclarent's enterprise field sales motion.
Stryker: Stryker is a diversified surgical device incumbent whose ENT and navigation offerings overlap with Acclarent's TruDi system across hospital surgical suites.
Olympus Corporation: Olympus is a major player in ENT endoscopy and rigid scopes used in sinus surgery, providing overlapping equipment to the same otolaryngology surgical centers Acclarent serves.

Others

Integra LifeSciences: Integra LifeSciences is Acclarent's parent company (acquired April 2024), operating the ENT surgical portfolio alongside neurosurgery and regenerative technology franchises.
Johnson & Johnson (Ethicon): Ethicon, J&J's surgical device division, owned Acclarent from 2010 to 2024 and continues to operate in overlapping surgical device categories with shared hospital customers.

Emerging players

Sinusys Corporation: Sinusys is an emerging player in sinus dilation and drug delivery technologies, competing in the same balloon sinuplasty category Acclarent pioneered.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Acclarent financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acclarent leadership team

Management profile

Number of profiles

Acclarent funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acclarent M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acclarent

What does Acclarent do?

Is Acclarent a public or private company?

Acclarent is a private company. It is classified as corporate owned and is currently operating.

When was Acclarent founded?

Acclarent was founded in 2004. It employs 251 to 500 people.

Where is Acclarent based?

Acclarent is headquartered in Menlo Park, United States, in the North America region.

How does Acclarent make money?

One revenue line is on record: medical Device Hardware Sales.

Who are Acclarent's main competitors?

Direct peers on record are Medtronic, Intersect ENT, Spirox / Entellus Medical (Stryker) and Karl Storz SE & Co. KG. Broad incumbents are Smith+Nephew, Stryker and Olympus Corporation. Others are Integra LifeSciences and Johnson & Johnson (Ethicon). Sinusys Corporation is listed as an emerging player.

Does Acclarent have an API?

No public API is recorded for Acclarent.

What industry is Acclarent in?

Acclarent's product category is ENT Surgical Devices. Its primary akta.pro industry code is HLAHADAG, Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT), with a secondary code of HLAKAMAA, General Otolaryngology (ENT). Its NAICS code is 339112 and its SIC code is 3841.